Replies to post #559440 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Thanks for reposting that again. The trial design was exemplary.

Well, the design was solid. Too bad the designed primary endpoints of PFS and OS both failed.

The fallback to comparison to other trials after knowing the failure of the designed endpoints is what many would call total nonsense.

[HyGro]

But yet it is not when you cheery-pick your sample (complete/near complete resection) and then compare to trials that did not screen for such a high level of health naïve GBM patients.

Dr. Ashcan didn't participate in the statisical analysis that was controlled and directed by Dr. Bosch, an NWBO employee, significant shareholder and had a clear conflict of interest,

Dr. Ashcan wasn't even honest with his UK peers by reporting the PFS results. At least the first TLD data reporting included that data.